Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 ...

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.

A month has gone by since the last earnings report for Alkermes (ALKS). Shares have lost about 2.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

Alkermes just unveiled an announcement. Alkermes plc shareholders, during their 2024 Annual Meeting, approved key amendments to the company’s stock plan, including a substantial ...

Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to 5%. JAMA study ...

The singer-songwriter talks about the importance of having the language to express one's experiences to others. Marcus King on Battling Feelings of “Terrible Hopelessness” with Meaningful Communicatio ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to ...